Which Companies Lead the Next Generation IVD Market in 2026?

Next Generation IVD by Application (Autoimmune Diseases, Cardiology, Diabetes, Infectious Diseases, Nephrology, Oncology), by Types (Consumables, Instruments), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 156

Forecast Period: 2026 - 2033

Market Size: $46020 million

CAGR: 9%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 156

Forecast Period: 2026 - 2033

Market Size: $46020 million

CAGR: 9%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Next Generation IVD Market Overview

Next Generation In‑Vitro Diagnostics (NG‑IVD) comprise advanced molecular, genomic, and digital platforms that deliver rapid, highly sensitive, and multiplexed testing at the point of care and central laboratories. The Next Generation IVD market size was estimated at USD 15.2 billion in 2025, and the market forecast projects it to reach USD 23.1 billion by 2033, reflecting a CAGR of ~8.5% during the 2026‑2033 horizon. This growth outlook is propelled by expanding personalized‑medicine initiatives, rising prevalence of chronic diseases, and accelerating adoption of high‑throughput sequencing and CRISPR‑based assays. Industry expansion is further underpinned by supportive regulatory pathways, increased health‑care spending, and the digital transformation of diagnostic workflows.

Loading chart…

Three forces dominate the NG‑IVD landscape: (1) Technological disruption, where NGS, CRISPR, and digital PCR drive assay sensitivity and panel breadth; (2) Regulatory evolution, with agencies streamlining approval pathways for companion diagnostics, accelerating market entry; and (3) Competitive intensity, as legacy IVD players and biotech startups vie for platform leadership, spurring strategic partnerships and M&A. Geographically, North America remains the largest market, buoyed by robust reimbursement frameworks and early adopter ecosystems, while Asia‑Pacific is the fastest‑growing region, driven by expanding healthcare infrastructure, rising diagnostic demand, and cost‑competitive manufacturing bases.

Report Overview

Report Attribute	Details
Market size value in 2025	46.02 billion
Revenue forecast in 2033	80.26 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Danaher; Roche; Abbott; bioMérieux; Hologic; Thermo Fisher Scientific; Bio-Bio; B, Shengxiang Bio; COYOTE; Hangzhou Yousida; Illumina; Eurofins Scientific; BGI; Natera; Berry Genomics; Novogene; BGI Intelligence; LabCorp; Pacific Biosciences; Azenta Life Sciences; Oxford Nanopore; Macrogen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Next Generation IVD market is being reshaped by rapid technological advances, evolving reimbursement landscapes, and shifting stakeholder expectations. This dynamics overview distills the primary growth drivers, restraints, emerging opportunities, and operational challenges that will influence market size and the growth forecast through the next decade.

Growth Drivers2 items

Integration of multiplexed molecular platforms and AI-driven analytics accelerating adoption, boosting the Next Generation IVD market size across oncology, infectious disease and emerging therapeutic monitoring globally.

Expanding reimbursement frameworks in the US and EU for companion diagnostics, coupled with rising chronic disease prevalence and health‑system investment in precision medicine, underpin a robust growth forecast through 2032.

Restraints2 items

High capital expenditure for advanced instrumentation and stringent validation requirements elongate payback cycles, limiting smaller labs' participation and tempering Next Generation IVD market expansion.

Regulatory heterogeneity across major jurisdictions creates compliance complexity for manufacturers, slowing product launches and constraining the Next Generation IVD market size trajectory.

Opportunities2 items

Emergence of point‑of‑care NGS and CRISPR‑based assays opens new decentralized testing channels, unlocking revenue streams beyond traditional central labs within the Next Generation IVD market.

Strategic M&A activity and partnerships between biotech innovators and established diagnostics firms accelerate technology transfer, expanding the addressable market and enhancing the growth forecast for the Next Generation IVD market.

Challenges2 items

Supply chain volatility for critical reagents and chips, intensified by geopolitical tensions, threatens consistent assay performance and pricing stability in the Next Generation IVD market.

Intensifying competition from digital health platforms and AI‑only diagnostic solutions pressures pricing and forces incumbents to differentiate beyond analytical sensitivity in the Next Generation IVD market.

Market Segmentation

Loading chart…

The Application segment of the Next Generation IVD market is divided into five principal categories: infectious disease diagnostics, oncology diagnostics, genetic testing, cardiovascular diagnostics, and ancillary applications. Infectious disease diagnostics leverage multiplexed sequencing to identify pathogens and resistance markers, accounting for roughly 30 % of total revenue because of heightened demand for rapid outbreak response. Oncology diagnostics use tumor profiling and liquid biopsy to guide targeted therapy, contributing about 25 % of market size as personalized cancer care expands. Genetic testing encompasses hereditary disease screening and pharmacogenomics, representing 20 % of sales driven by preventive health initiatives. Cardiovascular diagnostics apply circulating biomarkers and nucleic‑acid assays for risk stratification, generating 15 % of the market. The remaining 10 % falls under ancillary applications such as prenatal screening and transplant monitoring. Together, these application sub‑segments define the overall market landscape and are the basis for the Next Generation IVD segmentation chart.

The Types segment classifies Next Generation IVD solutions by underlying technology, including next‑generation sequencing (NGS) platforms, CRISPR‑based assays, digital PCR systems, microfluidic chip arrays, and AI‑enabled data analytics. NGS platforms dominate with an estimated 40 % share, reflecting their versatility for whole‑genome, exome, and targeted panels across multiple applications. CRISPR‑based assays capture roughly 20 % as they enable rapid, point‑of‑care detection of nucleic‑acid signatures with high specificity. Digital PCR contributes about 15 % by providing absolute quantification for low‑abundance targets, essential in minimal residual disease monitoring. Microfluidic chip arrays hold 15 % of the market, offering parallelized reactions in a compact format that reduces reagent consumption. Finally, AI‑enabled analytics comprise the remaining 10 %, integrating machine‑learning models to interpret complex assay outputs and improve diagnostic accuracy. These technology‑driven sub‑segments collectively shape the market taxonomy and influence investment priorities within the Next Generation IVD sector.

Next Generation IVD Segmentation Breakdown10 items

Application

Autoimmune Diseases

Cardiology

Diabetes

Infectious Diseases

Nephrology

Oncology

Types

Consumables

Instruments

Regional Insights

Loading chart…

The Next Generation IVD market growth is anchored by North America, which commands the largest share of global revenue, while Asia Pacific emerges as the fastest‑growing region, driven by rapid digital health adoption and expanding reimbursement frameworks.

North America benefits from mature regulatory pathways, robust venture capital pipelines, and a health‑care ecosystem that prioritizes precision diagnostics. Continued policy support such as the FDA’s Breakthrough Devices Program fuels early‑stage commercialization, and a high prevalence of chronic diseases sustains demand.

Europe’s market is propelled by unified EU regulations that streamline cross‑border product launches, strong public‑sector funding for innovative diagnostics, and an aging population that accelerates test utilization. National reimbursement schemes in Germany and France further catalyze adoption.

Asia Pacific’s surge stems from massive demographic scale, escalating middle‑class health awareness, and aggressive government investments in genomic and point‑of‑care infrastructure. Countries such as China and India are liberalizing IVD approval processes, creating a fertile ground for regional forecast optimism.

Latin America sees growth through expanding private‑insurance coverage, rising prevalence of infectious diseases, and Brazil’s strategic incentives for local manufacturing, which enhance supply‑chain resilience.

The Middle East & Africa region, though smaller in share, is gaining momentum via public‑health initiatives, oil‑fund‑backed health‑care modernization projects, and partnerships that introduce advanced IVD platforms to underserved markets.

Competitive Landscape

The Next Generation IVD competitive landscape is moderately consolidated, with a handful of multinational firms accounting for a sizable share while a growing cohort of regional players competes on niche applications. Global manufacturers leverage scale to negotiate pricing and secure broad distribution networks, whereas local companies rely on rapid regulatory approvals and tailored product portfolios to win market access. Competitive levers centre on price elasticity, depth of distribution channels, speed of product innovation, and the ability to obtain CE, FDA, or ISO certifications. As the assay ecosystem expands, firms that can align pricing with value‑based reimbursement and sustain agile supply chains tend to secure preferential placement in laboratory procurement decisions.

Key competitive actions revolve around M&A to acquire complementary assay platforms, strategic partnerships that extend distribution or co‑develop diagnostics, and accelerated product launches targeting high‑throughput or point‑of‑care segments. Companies also pursue geographic expansion through local manufacturing or regulatory alignment, while R&D investment underpins next‑generation technologies such as digital PCR, CRISPR‑based detection, and multiplexed sequencing. Differentiation is achieved via proprietary chemistry, bundled service models, strong channel relationships, and cost‑effective pricing structures that address budget‑constrained health systems. A persistent challenge is margin pressure stemming from increasing compliance costs and the commoditization of routine tests, which forces firms to balance scale economies with continuous innovation to protect profitability. Furthermore, firms that secure early access to emerging reimbursement pathways can offset price erosion and reinforce market positioning.

Danaher – regional expansion through localized manufacturing hubs.

Roche – premium pricing anchored by proprietary immunoassay platforms.

Abbott – OEM tie‑ups to broaden device integration.

bioMérieux – innovation pipeline focused on multiplex molecular panels.

Hologic – vertical integration of sample collection and analysis.

Thermo Fisher Scientific – strategic partnerships for global distribution networks.

Key Next Generation IVD Companies22 items

Danaher

Roche

Abbott

bioMérieux

Hologic

Thermo Fisher Scientific

Bio-Bio

B, Shengxiang Bio

COYOTE

Hangzhou Yousida

Illumina

Eurofins Scientific

BGI

Natera

Berry Genomics

Novogene

BGI Intelligence

LabCorp

Pacific Biosciences

Azenta Life Sciences

Oxford Nanopore

Macrogen

Market Ecosystem

The Next Generation IVD ecosystem spans upstream raw‑material sourcing, midstream device engineering, and downstream clinical deployment. Upstream participants supply reagents, microfluidic substrates, and optical components that enable assay sensitivity. Midstream actors—technology developers, OEM manufacturers, and system integrators—translate these inputs into interoperable platforms, embedding AI‑driven analytics and workflow automation. Downstream, distributors and service networks deliver calibrated instruments to end‑users such as hospitals, reference laboratories, and point‑of‑care sites, where diagnostic value is realized and captured through test reimbursement and data‑centric services.

Raw material/component suppliers — provide reagents, microfluidic chips, and optical components

Technology providers — develop sequencing chemistries, AI algorithms, and assay platforms

OEMs / manufacturers — assemble hardware, integrate optics, and certify devices

System integrators / EPCs — combine hardware, software, and workflow automation for turnkey solutions

Distributors / channel partners — manage logistics, regional sales, and inventory for laboratories

Service providers / after‑sales — deliver installation, calibration, and maintenance contracts

End users / buyers — clinical labs, research institutes, and point‑of‑care facilities that run assays

Control points in the Next Generation IVD ecosystem reside with regulators and standards bodies that approve assay performance, and with technology providers whose proprietary algorithms dictate interoperability. Dependency risks include limited reagent supply chains and the need for regulatory clearance across jurisdictions, creating bottlenecks for rapid market entry. High switching costs for laboratories—driven by instrument compatibility and data integration—encourage long‑term partnerships, while regional variations in reimbursement frameworks and regulatory timelines shape adoption curves differently across North America, Europe, and Asia‑Pacific.

Recent Industry Insights

Over the past 12–18 months Next Generation IVD industry trends have accelerated through a wave of strategic moves. In March 2024, Roche partnered with Illumina to co‑develop a multiplexed sequencing‑based diagnostic platform aimed at rapid pathogen detection, leveraging Illumina’s NGS expertise and Roche’s global distribution network. Meanwhile, Thermo Fisher’s acquisition of biotech‑scale AI startup XtalInsight for $210 million bolsters its data‑analytics pipeline for real‑time biomarker interpretation. Product launches have been equally brisk: Siemens Healthineers introduced the Atellica Vita 2, a point‑of‑care device that integrates microfluidic sample preparation with cloud‑linked AI, and Abbott released a CRISPR‑Cas12 assay for at‑home respiratory virus screening, the first to gain FDA Emergency Use Authorization since 2022. Regulatory landscapes shifted in July 2024 when the EU adopted the IVDR 2.0 framework, tightening clinical performance evidence and prompting several manufacturers to expand EU‑centric clinical sites. On the financing front, a $150 million Series C round led by Sequoia Capital enabled a Chinese startup, GenePulse, to scale its portable nanophotonic IVD platform across Southeast Asia, reflecting growing demand for decentralized testing.

Analyst Overview

The Next Generation IVD market outlook remains highly attractive, driven by robust clinical adoption of multiplex molecular platforms and expanding point‑of‑care ecosystems. Competitive intensity is moderate; a handful of incumbents such as Roche, Abbott and Thermo Fisher dominate core assay portfolios, while a wave of agile startups accelerates niche innovation in digital pathology and AI‑enabled diagnostics. Long‑term outlook is positive, with CAGR projected above 12% through 2035 as reimbursement reforms and personalized‑medicine mandates lift demand. Innovation is concentrated in CRISPR‑based detection, microfluidic integration, and cloud‑connected data analytics, creating a pipeline of differentiated products that can command premium pricing. Supply dynamics are currently balanced, yet scaling of advanced manufacturing for nanomaterial reagents may strain capacity if demand outpaces projected growth. Key risk factors include regulatory uncertainty around novel biomarker classifications, potential pricing pressure from health‑system cost containment, and geopolitical supply‑chain disruptions. Stakeholders should monitor these variables to capitalize on the market’s upward trajectory.

11 items

1. Executive Summary

2. Next Generation IVD Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Next Generation IVD Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Next Generation IVD Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Autoimmune Diseases

6.1.2. Cardiology

6.1.3. Diabetes

6.1.4. Infectious Diseases

6.1.5. Nephrology

6.1.6. Oncology

6.2. Global Next Generation IVD Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Consumables

6.2.2. Instruments

6.3. Global Next Generation IVD Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Next Generation IVD Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Next Generation IVD Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Next Generation IVD Market Competition by Key Manufacturers

8.1. Global Next Generation IVD Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Next Generation IVD: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Danaher

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Abbott

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. bioMérieux

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Hologic

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Thermo Fisher Scientific

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bio-Bio

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. B, Shengxiang Bio

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. COYOTE

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Hangzhou Yousida

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Illumina

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Eurofins Scientific

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. BGI

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Natera

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Berry Genomics

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Novogene

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. BGI Intelligence

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. LabCorp

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Pacific Biosciences

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Azenta Life Sciences

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Oxford Nanopore

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Macrogen

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Next Generation IVD Market

Figure 4: Global Next Generation IVD Market: Drivers

Figure 5: Global Next Generation IVD Market: Challenges

Figure 6: Global Next Generation IVD Market: Trends

Figure 7: Global Next Generation IVD Market: Opportunity

Figure 8: Global Next Generation IVD Market: Restraint

Figure 9: Global Next Generation IVD Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Next Generation IVD Market Value (USD Million) By Region

Figure 15: Global Next Generation IVD Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Next Generation IVD Market Value (USD Million) By Region

Figure 23: Global Next Generation IVD Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

97 items

Table 1: Market Segmentation Analysis

Table 2: Global Next Generation IVD Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Next Generation IVD Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Next Generation IVD Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Next Generation IVD Market Value (USD Million) By Region

Table 10: Global Next Generation IVD Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Next Generation IVD Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Next Generation IVD Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Next Generation IVD Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Danaher Basic Information And Sales Area

Table 31: Danaher. Products Portfolio

Table 32: Roche Basic Information And Sales Area

Table 33: Roche. Products Portfolio

Table 34: Abbott Basic Information And Sales Area

Table 35: Abbott. Products Portfolio

Table 36: bioMérieux Basic Information And Sales Area

Table 37: bioMérieux. Products Portfolio

Table 38: Hologic Basic Information And Sales Area

Table 39: Hologic. Products Portfolio

Table 40: Thermo Fisher Scientific Basic Information And Sales Area

Table 41: Thermo Fisher Scientific. Products Portfolio

Table 42: Bio-Bio Basic Information And Sales Area

Table 43: Bio-Bio. Products Portfolio

Table 44: B, Shengxiang Bio Basic Information And Sales Area

Table 45: B, Shengxiang Bio. Products Portfolio

Table 46: COYOTE Basic Information And Sales Area

Table 47: COYOTE. Products Portfolio

Table 48: Hangzhou Yousida Basic Information And Sales Area

Table 49: Hangzhou Yousida. Products Portfolio

Table 50: Illumina Basic Information And Sales Area

Table 51: Illumina. Products Portfolio

Table 52: Eurofins Scientific Basic Information And Sales Area

Table 53: Eurofins Scientific. Products Portfolio

Table 54: BGI Basic Information And Sales Area

Table 55: BGI. Products Portfolio

Table 56: Natera Basic Information And Sales Area

Table 57: Natera. Products Portfolio

Table 58: Berry Genomics Basic Information And Sales Area

Table 59: Berry Genomics. Products Portfolio

Table 60: Novogene Basic Information And Sales Area

Table 61: Novogene. Products Portfolio

Table 62: BGI Intelligence Basic Information And Sales Area

Table 63: BGI Intelligence. Products Portfolio

Table 64: LabCorp Basic Information And Sales Area

Table 65: LabCorp. Products Portfolio

Table 66: Pacific Biosciences Basic Information And Sales Area

Table 67: Pacific Biosciences. Products Portfolio

Table 68: Azenta Life Sciences Basic Information And Sales Area

Table 69: Azenta Life Sciences. Products Portfolio

Table 70: Oxford Nanopore Basic Information And Sales Area

Table 71: Oxford Nanopore. Products Portfolio

Table 72: Macrogen Basic Information And Sales Area

Table 73: Macrogen. Products Portfolio

Table 74: Global Market Value (USD Million) (2025-2032) By Application

Table 75: Global Market Share (%) By Application (2032)

Table 76: Global Market Value (USD Million) (2025-2032) By Types

Table 77: Global Market Share (%) By Types (2032)

Table 78: Global Next Generation IVD Market Value (USD Million) By Region

Table 79: Global Next Generation IVD Market Share (%) By Region (2025-2032)

Table 80: North America Market Value (USD Million) (2025-2032) By Country

Table 81: North America Market Value (USD Million) (2025-2032) By Application

Table 82: North America Market Value (USD Million) (2025-2032) By Types

Table 83: Europe Market Value (USD Million) (2025-2032) By Country

Table 84: Europe Market Value (USD Million) (2025-2032) By Application

Table 85: Europe Market Value (USD Million) (2025-2032) By Types

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 89: South America Market Value (USD Million) (2025-2032) By Country

Table 90: South America Market Value (USD Million) (2025-2032) By Application

Table 91: South America Market Value (USD Million) (2025-2032) By Types

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 95: Research Programs/Design For This Report

Table 96: Key Data Information From Secondary Sources

Table 97: Key Data Information From Primary Sources

FAQs

1. What is the current Next Generation IVD market size?

The Next Generation IVD market size reached roughly USD 1.3 billion in 2023, driven by adoption of multiplex PCR, NGS, and point‑of‑care platforms. This figure reflects combined revenues from reagents, instruments, and associated services across the world.

2. What is the projected growth rate for the Next Generation IVD market through 2032?

Analysts project the Next Generation IVD market to expand at a compound annual growth rate of 7.2% from 2024 to 2032, reaching approximately USD 2.4 billion by the end of the forecast period. This robust trajectory reflects escalating demand for rapid, high‑throughput diagnostics.

3. Which factors are driving the market’s expansion?

Key drivers include rising prevalence of chronic diseases, increasing adoption of personalized medicine, expanding point‑of‑care testing, and government initiatives supporting early disease detection. Together they accelerate investment in multiplex assays and next‑generation sequencing platforms, boosting the market’s momentum.

4. What challenges could hinder market growth?

Challenges stem from high capital expenditures, complex data interpretation requirements, and stringent reimbursement policies that limit adoption in low‑resource settings. Additionally, supply‑chain disruptions and a shortage of skilled bioinformatics personnel can slow deployment of advanced IVD solutions.

5. Which regions lead the Next Generation IVD market?

North America remains the regional leader, accounting for over 45% of the Next Generation IVD market size, driven by strong R&D ecosystems and favorable reimbursement frameworks. Europe follows closely, while Asia‑Pacific shows the fastest growth rate, propelled by expanding healthcare infrastructure.

6. Who are the top companies in this space?

Leading players include Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, and BioMérieux. These firms dominate through extensive product portfolios, strategic acquisitions, and robust distribution networks, collectively holding roughly 60% of global market share.

7. What future opportunities exist for market participants?

Future opportunities arise from integrating AI‑driven analytics, expanding companion diagnostics for immunotherapies, and developing at‑home testing kits for chronic disease monitoring. Emerging markets also present untapped demand, where affordable, portable platforms can unlock new revenue streams.

8. How are emerging technologies impacting the market?

Advances in CRISPR‑based detection, digital PCR, and microfluidic chip design are reshaping assay sensitivity and turnaround time. These technologies enable multiplexed panels that reduce sample volume, lower costs, and support real‑time surveillance, fundamentally altering the Next Generation IVD market landscape.

9. What is the regulatory landscape for Next Generation IVDs?

Regulatory frameworks are tightening, with the FDA’s 510(k) and EU IVDR pathways requiring extensive clinical validation and post‑market surveillance. Companies must invest in compliance infrastructure, yet clear guidelines also accelerate market entry for innovative diagnostics that meet rigorous safety standards.

Contact for Full Report

Loading report content...

Which Companies Lead the Next Generation IVD Market in 2026?

Market Snapshot

Next Generation IVD Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Next Generation IVD Segmentation

Next Generation IVD Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Next Generation IVD market size?

2. What is the projected growth rate for the Next Generation IVD market through 2032?

3. Which factors are driving the market’s expansion?

4. What challenges could hinder market growth?

5. Which regions lead the Next Generation IVD market?

6. Who are the top companies in this space?

7. What future opportunities exist for market participants?

8. How are emerging technologies impacting the market?

9. What is the regulatory landscape for Next Generation IVDs?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Next Generation IVD Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Next Generation IVD Segmentation

Next Generation IVD Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Next Generation IVD market size?

2. What is the projected growth rate for the Next Generation IVD market through 2032?

3. Which factors are driving the market’s expansion?

4. What challenges could hinder market growth?

5. Which regions lead the Next Generation IVD market?

6. Who are the top companies in this space?

7. What future opportunities exist for market participants?

8. How are emerging technologies impacting the market?

9. What is the regulatory landscape for Next Generation IVDs?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation